NCT00132067View on ClinicalTrials.gov

Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

July 31, 2008

Conditions
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Interventions
DRUG

vorinostat

Given orally

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00132067 - Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | Biotech Hunter | Biotech Hunter